The anti-proliferative and apoptotic activities of PDT in combination with the PPARγ ligand troglitazone and provide a strong rationale for testing the therapeutic potential of combination treatment in colon cancer [134]. The gene discussed is PPARG; the disease is colonic neoplasm.